Anavex Life Sciences Corp (AVXL)

[JB3729]

This patent is a combination patent as is the Anavex Plus patent application. I think that protection for A2-73, when dosed by itself, will come from FDA approvals of Orphan Drug Designations that dose A2-73 alone.

I think Anavex will be assigned plenty of patents and FDA approval exclusivity in the future.

I am not a patent expert.

SUMMARY OF THE INVENTION

In view of the foregoing disadvantages inherent in the prior art, the present invention provides an improved sigma(a) receptor ligands and method for using, and overcomes the above-mentioned disadvantages and drawbacks of the prior art. As such, the general purpose of the present invention, which will be described subsequently in greater detail, is to provide a new and improved sigma(a) receptor ligands and method which has all the advantages of the prior art mentioned heretofore and many novel features that result in a sigma(a) receptor ligands which is not anticipated, rendered obvious, suggested, or even implied by the prior art, either alone or in any combination thereof.

To attain this, the present invention essentially comprises a method for using a compound including sigma(a)-receptor ligands and a sigma(a) ligands generics. The method includes the providing of a compound having a sigma(a)-receptor ligands and a sigma(a) ligands generics, wherein the sigma(a) ligands generics is selected from Quinacrine, analogues of Quinacrine, Methylene blue, analogues of Methylene blue, Astemizole, and analogues of Astemizole. Then method further includes using the composition for the preparation of pharmaceuticals.

The pharmaceuticals have anticancer, antimetastatic and antiviral activity associated with analgesic properties.